Impact of sarcopenia on dose limiting toxicities in metastatic colorectal cancer patients (mCRC pts) receiving palliative systemic treatment
Sophie A. Kurk(Utrecht University), Anne M. May(Utrecht University), Frans Erdkamp, Cornelis J.A. Punt(Utrecht University), Miriam Koopman(Utrecht University), Rebecca K. Stellato(University Medical Center Utrecht), FE de Jongh(Leiden University Medical Center), P. Kint(Amphia Ziekenhuis), Lieke H. J. Simkens(Academic Medical Center), Manuel L. R. Tjin‐A‐Ton(Ziekenhuis Rivierenland), Petra H.M. Peeters(University Medical Center Utrecht), Bea C. Tanis(Leiden University Medical Center), Marion Jourdan(Nutricia Research (Netherlands)), A. van der Velden(Tergooi), Sandra A. Radema(Radboud University Nijmegen), Bram Dorresteijn(Nutricia Research (Netherlands)), G.J. Creemers(Radboud University Nijmegen), Boelo Jan Poppema(Dialyse Centrum Groningen)
Cited by 4
Related Papers
Preoperative Chemoradiotherapy for Esophageal or Junctional Cancer
|New England Journal of Medicine|2012|5.5k
Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial
|The Lancet Oncology|2015|2.6k
Genome-wide cell-free DNA fragmentation in patients with cancer
|Nature|2019|1.5k
Direct detection of early-stage cancers using circulating tumor DNA
|Science Translational Medicine|2017|1.1k